Mehjabin Zahir, MD
Pulmonary Disease · Brooklyn, NYNPI 1134367626
Payments from drug & device makers
Across 530 payments — averaging $18.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$2K
- Boehringer Ingelheim$732
- Sanofi$708
- Regeneron Healthcare Solutions, Inc.$545
- Philips North America LLC$366
- plus $3K from 25 others
What the payments were for
- Food & beverage$9,822100%
- Education$260%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 120 | $2,425 |
| GSK | 156 | $2,419 |
| Boehringer Ingelheim | 40 | $732 |
| Sanofi | 31 | $708 |
| Regeneron Healthcare Solutions, Inc. | 25 | $545 |
| Philips North America LLC | 23 | $366 |
| Grifols USA, LLC | 16 | $303 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $295 |
| Actelion Pharmaceuticals US, Inc. | 11 | $294 |
| Johnson & Johnson | 15 | $290 |
| Amgen | 7 | $170 |
| Mallinckrodt Hospital Products Inc. | 7 | $130 |
| Pfizer | 6 | $115 |
| Merck | 8 | $111 |
| Mylan Specialty L.p. | 6 | $107 |
| Verona Pharma, Inc. | 4 | $95 |
| Pulmonx Corporation | 3 | $92 |
| Viatris Specialty LLC | 4 | $84 |
| Paratek Pharmaceuticals, Inc. | 5 | $74 |
| Shire North American Group Inc | 3 | $72 |
| AbbVie(2 entities) | 3 | $71 |
| ANI Pharmaceuticals, Inc. | 3 | $66 |
| Insmed, Inc. | 4 | $66 |
| United Therapeutics Corporation | 3 | $55 |
| Sunovion Pharmaceuticals Inc. | 4 | $39 |
| Genentech USA, Inc. | 2 | $26 |
| Circassia Inc. | 2 | $25 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Gilead | 1 | $18 |
| Novartis | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$125
How this compares
$9,849 in reported general payments places this provider in the 75th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 620 | $558,672 |
| NucalaMepolizumab | 19 | $155,626 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 162 | $142,386 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 155 | $126,731 |
| Spiriva RespimatTiotropium Bromide | 127 | $105,972 |
| Incruse ElliptaUmeclidinium Bromide | 110 | $60,003 |
| Breo ElliptaFluticasone/Vilanterol | 82 | $49,610 |
| SymbicortBudesonide/Formoterol Fumarate | 130 | $48,614 |
| Dupixent PenDupilumab | 13 | $48,613 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 728 | $28,553 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 25 | $25,502 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 17 | $23,611 |
| EliquisApixaban | 27 | $23,483 |
| Spiriva HandihalerTiotropium Bromide | 14 | $19,839 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 79 | $19,175 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Incruse Ellipta, Breo Ellipta | $2,419 | $950,642986 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $2,425 | $202,743320 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $732 | $155,085169 claims |
| PfizerEliquis | $115 | $23,48327 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Brooklyn
- Ali El AtatBrooklyn$547K
- Sunil MehraBrooklyn$388K
- Aaliya BurzaBrooklyn$334K
- Xiaojun YanBrooklyn$249K
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- R WhiteRochester$3.1M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.